END-AF 1

Clinical randomised Phase II trial of AP31969 versus Placebo for Rhythm control of atrial fibrillation

Stage: inclusie
Medicine: AP31969
Population: Ritme
Phase: II
First Patient In: 1 November 2025
Last Patient In: 1 May 2026
Last Patient Last Visit: 1 October 2026

Inclusion period, 153 days remaining

Study Director

dr. R.G. Tieleman

Cardioloog

Office Contact

M.J. van Doorn

WCN